Skip to main content

Table 2 Main results of pooled HRs in the meta-analysis

From: Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis

  Study number Sample size OR/HR (95% CI) P value z Heterogeneity Publication bias (Eggers test)
I2 (%) Ph T-value Pbias
Overall TNM stage (III/IV vs I/II) 70 11,901 2.19 (1.84–2.61) P < 0.001 8.83 80.74 P < 0.001 2.40 0.018
Overall tumor differentiation (poor vs well/moderate) 59 9251 1.25 (1.01–1.55) 0.035 2.10 82.38 P < 0.001 1.84 0.07
Overall lymph node metastasis (Yes vs No) 76 13,172 1.76 (1.54–2.02) 0.00 8.23 73.57 P < 0.001 2.37 0.019
Overall OS 78 13,482 1.65 (1.54–1.77) 0.00 14.00 56.74 P < 0.001 3.70 P < 0.001
Overall DFS/RFS 18 1788 2.35 (1.90–2.89) P < 0.001 7.96 46.93 0.015 1.63 0.12
Overall CSS/ DSS 8 1462 1.69 (1.33–2.15) P < 0.001 4.32 49.04 0.056 1.00 0.35
CD44s
 TNM stage (III/IV vs I/II) 9 1331 2.74 (1.39–5.38) 0.003 2.93 83.96 P < 0.001 1.55 0.163
 Tumor differentiation (poor vs well/moderate) 9 1177 2.82 (1.50–5.30) 0.001 3.23 75.38 P < 0.001 0.71 0.49
 Lymph node metastasis (Yes vs No) 11 1638 1.64 (1.13–2.38) 0.009 2.62 56.83 0.010 1.65 0.13
 OS 11 1669 1.97 (1.55–2.50) P < 0.001 5.61 54.99 0.014 1.62 0.13
 DFS/RFS 5 516 2.74 (1.80–4.17) P < 0.001 4.69 42.23 0.14
 CSS/DSS 2 246 2.59 (1.32–5.06) 0.005 2.78 0.00 0.65
CD44V6
 TNM stage (III/IV vs I/II) 3 311 2.50 (1.22–5.14) 0.012 2.51 70.46 0.034 0.40 0.75
 Tumor differentiation (poor vs well/moderate) 5 684 0.93 (0.35–2.42) 0.88 − 0.14 86.80 P < 0.001 0.55 0.61
 Lymph node metastasis (Yes vs No) 5 684 2.26 (1.46–3.51) P < 0.001 3.65 25.64 0.25 1.68 0.19
 OS 3 512 1.81 (1.29–2.53) 0.001 3.45 0.00 0.82 2.34 0.25
 CSS/DSS 3 295 3.29 (1.46–7.43) 0.004 2.87 61.63 0.10
CD44V9
 TNM stage (III/IV vs I/II) 2 637 5.39 (2.70–10.77) P < 0.001 4.78 7.26 0.29
 Tumor differentiation (poor vs well/moderate) 3 559 0.98 (0.37–2.58) 0.98 − 0.025 84.72 0.001 14.65 0.043
 Lymph node metastasis (Yes vs No) 3 559 1.52 (0.91–2.52) 0.10 1.61 40.74 0.18 8.64 0.073
 OS 2 619 1.22 (0.96–1.54) 0.08 1.69 P < 0.001 0.74
 DFS/RFS 2 168 8.60 (1.70–43.57) 0.009 2.61 77.51 0.035
 CSS/DSS 2 246 1.67 (0.52–5.35) 0.38 0.86 0.00 0.48
CD133
 TNM stage (III/IV vs I/II) 11 1853 2.67 (1.84–3.89) P < 0.001 5.16 54.01 0.016 0.25 0.80
 Tumor differentiation (poor vs well/moderate) 10 1677 0.87 (0.56–1.34) 0.53 − 0.62 70.18 P < 0.001 2.09 0.06
 Lymph node metastasis (Yes vs No) 11 1847 1.85 (1.22–2.79) 0.003 2.93 65.05 0.001 0.99 0.34
 OS 12 1939 1.74 (1.52–2.01) P < 0.001 7.87 0.00 0.55 1.83 0.09
 DFS/RFS 3 343 2.59 (1.74–3.85) P < 0.001 4.69 0.00 0.64
Sox-2
 TNM stage (III/IV vs I/II) 5 732 1.37 (0.65–2.90) 0.40 0.83 77.22 0.002 1.55 0.21
 Tumor differentiation (poor vs well/moderate) 2 119 1.21 (0.57–2.59) 0.60 0.51 23.37 0.25
 Lymph node metastasis (Yes vs No) 5 732 1.96 (1.40–2.73) P < 0.001 3.99 0.00 0.42 0.84 0.46
 OS 6 804 1.73 (1.37–2.18) P < 0.001 4.63 0.00 0.78 0.59 0.58
 DFS/RFS 1 69 1.31 (0.68–2.49) 0.41 0.82 0.00 1
Oct-4
 TNM stage (III/IV vs I/II) 6 1014 2.25 (1.09–4.66) 0.028 2.19 81.91 P < 0.001 0.79 0.47
 Tumor differentiation (poor vs well/moderate) 5 724 1.97 (0.86–4.50) 0.10 1.60 75.47 0.003 0.53 0.62
 Lymph node metastasis (Yes vs No) 6 1014 2.70 (1.09–6.68) 0.031 2.15 88.63 P < 0.001 1.15 0.31
 OS 7 1086 1.87 (1.48–2.35) 0.00 5.37 4.88 0.38 0.21 0.83
 DFS/RFS 2 114 2.18 (1.06–4.48) 0.023 2.13 11.13 0.28
ALDH1
 TNM stage (III/IV vs I/II) 4 760 3.66 (1.75–7.64) 0.001 3.45 74.19 0.009 1.31 0.31
 Tumor differentiation (poor vs well/moderate) 3 539 2.73 (0.43–17.19) 0.28 1.07 93.25 P < 0.001 4.6 0.13
 Lymph node metastasis (Yes vs No) 4 760 2.50 (0.96–6.45) 0.058 1.89 88.08 P < 0.001 0.09 0.93
 OS 5 851 1.65 (1.32–2.05) P < 0.001 4.53 0.00 0.49 2.60 0.08
 DFS/RFS 2 307 1.49 (0.73–3.00) 0.27 1.10 56.39 0.13
LGR-5
 TNM stage (III/IV vs I/II) 5 1392 1.31 (0.46–3.74) 0.60 0.51 94.11 P < 0.001 0.58 0.6
 Tumor differentiation (poor vs well/moderate) 5 1423 1.04 (0.50–2.13) 0.91 0.10 87.79 P < 0.001 0.36 0.73
 Lymph node metastasis (Yes vs No) 6 1879 1.21 (0.70–2.09) 0.48 0.70 84.70 P < 0.001 0.01 0.98
 OS 5 1879 1.26 (0.97–1.63) 0.075 1.78 60.45 0.039 1.03 0.37
 CSS/DSS 1 456 1.02 (0.67–1.54) 0.90 0.11 0.00 1.00
Bmi-1
 TNM stage (III/IV vs I/II) 4 792 2.85 (1.04–7.81) 0.041 2.04 88.46 P < 0.001 1.07 0.36
 Tumor differentiation (poor vs well/moderate) 4 792 1.14 (0.70–1.85) 0.57 0.55 51.72 0.10 0.09 0.93
 Lymph node metastasis (Yes vs No) 5 1101 2.26 (1.19–4.26) 0.012 2.51 76.82 0.002 1.13 0.33
 OS 4 882 1.32 (0.77–2.27) 0.30 1.06 84.49 P < 0.001 1.57 0.25
 CSS/DSS 1 219 1.97 (1.35–2.87) P < 0.001 3.52 0.00 1.00
Nanog
 TNM stage (III/IV vs I/II) 3 464 1.34 (0.78–2.31) 0.27 1.08 0.86 P < 0.001 0.49 0.70
 Tumor differentiation (poor vs well/moderate) 2 174 1.89 (0.06–55.82) 0.71 0.37 93.05 P < 0.001
 Lymph node metastasis (Yes vs No) 3 464 1.49 (0.73–3.02) 0.26 1.10 44.43 0.16 0.71 0.60
 OS 3 464 1.59 (0.68–3.77) 0.28 1.07 80.97 0.005 0.93 0.52
 DFS/RFS 1 69 2.09 (0.92–4.70) 0.075 1.77 0.00 1
CD24
 TNM stage (III/IV vs I/II) 5 905 1.31 (0.87–1.98) 0.18 1.32 43.46 0.13 0.91 0.42
  Tumor differentiation (poor vs well/moderate) 2 393 1.10 (0.18–6.46) 0.91 0.10 90.02 0.002
 Lymph node metastasis (Yes vs No) 5 905 1.40 (1.04–1.89) 0.026 2.23 20.17 0.28 0.46 0.67
 OS 5 905 1.73 (1.25–2.4) 0.001 4.10 35.46 0.18 2.71 0.07
 Gli-1
 TNM stage (III/IV vs I/II) 6 614 4.00 (1.58–10.13) 0.003 2.93 79.50 P < 0.001 1.07 0.34
 Tumor differentiation (poor vs well/moderate) 4 403 1.66 (0.81–3.40) 0.16 1.39 57.08 0.07 0.93 0.44
 Lymph node metastasis (Yes vs No) 5 493 3.04 (1.62–5.71) 0.001 3.47 51.59 0.08 0.60 0.59
 OS 8 776 1.75 (1.34–2.31) 0.00 4.06 7.79 0.37 0.14 0.88
 DFS/RFS 1 101 3.40 (1.30–8.7) 0.012 2.52 0.00 1
Shh
 TNM stage (III/IV vs I/II) 7 1096 2.19 (0.97–4.94) 0.056 1.90 86.32 P < 0.001 3.12 0.026
 Tumor differentiation (poor vs well/moderate) 5 687 1.02 (0.24–4.30) 0.97 0.037 90.31 P < 0.001 1.63 0.20
 Lymph node metastasis (Yes vs No) 7 1096 1.14 (0.54–2.39) 0.73 0.34 85.02 P < 0.001 0.48 0.64
  OS 7 1096 1.27 (0.78–2.05) 0.32 0.99 76.23 P < 0.001 0.72 0.49
 DFS/RFS 1 101 2.75 (1.15–6.54) 0.02 2.28 0.00 1
  1. Ph: The p-value of heterogeneity; P bias: The p-value of Egger test for assessing publication bias; OS: Overall survival; DFS: Disease-free survival; RFS: Relapse-free survival; CSS: Cancer-specific survival; DSS: Disease-specific survival